Worth further discussion.. I posted some relevant, accurate & timely updates a few days ago.
Interestingly overwritten by for the most part, relevant to the biotech industry, but not directly related to Onc.
So: I'll try this again.
1. The Onc San Diego office is up for lease.
2. The V.P of USA business & development has left the company. He took his options & left. Early December.
3. Onc has said nothing about this change. Andrew G. Is now gone from the " mangement" page of their web site.
obviouoy they are closing the USA footprint.
Why?
& why no updates?
Obviously something is in- process. Not a random sequence of events.
My continued speculation is that of a buyout. Requiring a NDA & news blackout.
other options are plentry.
regardless I'm surprised ( there is that word again), no update today.
BTW, since inception & incorporation & part of corporate stratagy has always been to get Pela far enough & then partner or sell.
" going it alone" Would require not only huge funds, but also a complete rewrite of corporate direction.
up to & including the $350million shelf prospectus...would need to be rewritten, approved by board.
That option imho is a non- starter.
regardless, stay tuned.
Has been a very long ride. The next chapter will be revealed very soon.
As an investor new, old, or just not yet?
The science looks good. Roche is in deep with gobblet.
The business model moving forward?
it can not continue as- is for much longer.
Could be a truly binary investment right now. Quick resolution & upside. Or middle of the road re- organization.
again my opinion & thoughts. The buyout is at the lawyer & accountant stage.
Andrew left for greener pastures. Not needed in the new format.
The new hire positions? Obviously part of the future plans.